Portal:ExRNA/FeaturedPathways
From WikiPathways
(Added WP4336 and WP4337) |
Current revision (21:17, 13 May 2019) (view source) (removed deleted pathway) |
||
(11 intermediate revisions not shown.) | |||
Line 4: | Line 4: | ||
|width=100px|{{#pwImage:Pathway:WP2865|250px||IL1 and megakaryotyces in obesity}} | |width=100px|{{#pwImage:Pathway:WP2865|250px||IL1 and megakaryotyces in obesity}} | ||
[http://dx.doi.org/10.1161/ATVBAHA.113.302700 Beaulieu et al. Interleukin 1 receptor 1 and interleukin 1beta regulate megakaryocyte maturation, platelet activation, and transcript profile during inflammation in mice and humans] | [http://dx.doi.org/10.1161/ATVBAHA.113.302700 Beaulieu et al. Interleukin 1 receptor 1 and interleukin 1beta regulate megakaryocyte maturation, platelet activation, and transcript profile during inflammation in mice and humans] | ||
- | |width=100px|{{#pwImage:Pathway:WP2805|250px|| | + | |width=100px|{{#pwImage:Pathway:WP2805|250px||miRNA mechanism of action and biogenesis}} |
[http://dx.doi.org/10.1016/j.addr.2013.12.008 Ozpolat et al. Liposomal siRNA nanocarriers for cancer therapy] | [http://dx.doi.org/10.1016/j.addr.2013.12.008 Ozpolat et al. Liposomal siRNA nanocarriers for cancer therapy] | ||
[http://dx.doi.org/10.1016/j.tig.2014.05.003 Thomas et al. Eri1: a conserved enzyme at the crossroads of multiple RNA-processing pathways] | [http://dx.doi.org/10.1016/j.tig.2014.05.003 Thomas et al. Eri1: a conserved enzyme at the crossroads of multiple RNA-processing pathways] | ||
Line 12: | Line 12: | ||
|width=100px|{{#pwImage:Pathway:WP2868|250px||TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer}} | |width=100px|{{#pwImage:Pathway:WP2868|250px||TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer}} | ||
[http://dx.doi.org/10.1002/msb.20134892 Yang et al. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer] | [http://dx.doi.org/10.1002/msb.20134892 Yang et al. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer] | ||
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP3674|250px||mir34a and TGIF2 in osteoclastogenesis}} |
[http://dx.doi.org/10.1038/nature13375 Krzeszinski et al. miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2] | [http://dx.doi.org/10.1038/nature13375 Krzeszinski et al. miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2] | ||
|width=100px|{{#pwImage:Pathway:WP2811|250px||mir219 in Oligodendrocyte Differentiation and Myelination}} | |width=100px|{{#pwImage:Pathway:WP2811|250px||mir219 in Oligodendrocyte Differentiation and Myelination}} | ||
Line 37: | Line 37: | ||
[http://www.ncbi.nlm.nih.gov/pubmed/27013343 Parasramka et al. Long non-coding RNAs as novel targets for therapy in hepatocellular carcinoma] | [http://www.ncbi.nlm.nih.gov/pubmed/27013343 Parasramka et al. Long non-coding RNAs as novel targets for therapy in hepatocellular carcinoma] | ||
|- | |- | ||
- | |width=100px|{{#pwimage:Pathway: | + | |width=100px|{{#pwimage:Pathway:WP3926|250px||ApoE and miR-146 in inflammation and atherosclerosis}} |
[http://www.ncbi.nlm.nih.gov/pubmed/25904598 Li et al. Apolipoprotein E enhances microRNA-146a in monocytes and macrophages to suppress nuclear factor-κB-driven inflammation and atherosclerosis] | [http://www.ncbi.nlm.nih.gov/pubmed/25904598 Li et al. Apolipoprotein E enhances microRNA-146a in monocytes and macrophages to suppress nuclear factor-κB-driven inflammation and atherosclerosis] | ||
|width=100px|{{#pwimage:Pathway:WP3593|250px||miR-148a/miR-31/FIH1/HIF1α-Notch signaling in glioblastoma}} | |width=100px|{{#pwimage:Pathway:WP3593|250px||miR-148a/miR-31/FIH1/HIF1α-Notch signaling in glioblastoma}} | ||
Line 73: | Line 73: | ||
[http://www.ncbi.nlm.nih.gov/pubmed/28438689 Klingenberg et al. Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets] | [http://www.ncbi.nlm.nih.gov/pubmed/28438689 Klingenberg et al. Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets] | ||
|- | |- | ||
- | |width=100px|{{#pwimage:Pathway: | + | |width=100px|{{#pwimage:Pathway:WP4398|250px||PDGFRα and STMN1 cooperate to exacerbate the cytotoxic effects of vinblastine}} |
- | |width=100px|{{#pwimage:Pathway: | + | [https://www.ncbi.nlm.nih.gov/pubmed/30082792 Jun et al. A PDGFRα-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine] |
+ | |width=100px|{{#pwimage:Pathway:WP4397|250px||Model for regulation of MSMP expression in cancer cells and its proangiogenic role in ovarian tumors}} | ||
+ | [https://www.ncbi.nlm.nih.gov/pubmed/29059175 Mitamara et al. Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP)] | ||
+ | |width=100px|{{#pwimage:Pathway:WP4399|250px||MicroRNA network associated with Chronic lymphocytic leukemia}} | ||
+ | [http://www.ncbi.nlm.nih.gov/pubmed/27568792 Ciccone and Calin, MicroRNAs in Chronic Lymphocytic Leukemia: An Old Disease with New Genetic Insights] | ||
+ | |width=100px|{{#pwimage:Pathway:WP4400|250px||FABP4 in ovarian cancer}} | ||
+ | [https://www.ncbi.nlm.nih.gov/pubmed/30050129 Gharpure et al, FABP4 as a key determinant of metastatic potential of ovarian cancer] | ||
+ | |- | ||
+ | |width=100px|{{#pwimage:Pathway:WP4462|250px||Platelet-mediated interactions with vascular and circulating cells}} | ||
+ | [https://www.ncbi.nlm.nih.gov/pubmed/29348254 Koupenova et al, Circulating Platelets as Mediators of Immunity, Inflammation, and Thrombosis] | ||
+ | |width=100px|{{#pwimage:Pathway:Pathway:WP4474|250px||Circulating monocytes and cardiac macrophages in diastolic dysfunction}} | ||
+ | [https://www.ncbi.nlm.nih.gov/pubmed/29348254 Hulsmans et al, Cardiac macrophages promote diastolic dysfunction] | ||
+ | |width=100px|{{#pwimage:Pathway:Pathway:WP4566|250px||Translational regulation by PDGFRα}} | ||
+ | [https://www.ncbi.nlm.nih.gov/pubmed/30456354 Zhou et al, Chronic platelet-derived growth factor receptor signaling exerts control over initiation of protein translation in glioma] | ||
+ | |width=100px|{{#pwimage:Pathway:Pathway:WP4560|250px||MFAP5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement}} | ||
+ | [https://www.ncbi.nlm.nih.gov/pubmed/29251630 Leung et al, Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance] | ||
+ | |- | ||
+ | |width=100px|{{#pwimage:Pathway:Pathway:WP4559|250px||Interactions between immune cells and microRNAs in tumor microenvironment}} | ||
+ | [https://www.ncbi.nlm.nih.gov/pubmed/30578699 Cortez et al, Role of miRNAs in immune responses and immunotherapy in cancer] | ||
|width=100px|{{#pwimage:Pathway:WP2059|250px||Alzheimers Disease}} | |width=100px|{{#pwimage:Pathway:WP2059|250px||Alzheimers Disease}} | ||
|width=100px|{{#pwimage:Pathway:WP2371|250px||Parkinsons Disease}} | |width=100px|{{#pwimage:Pathway:WP2371|250px||Parkinsons Disease}} | ||
+ | |width=100px|{{#pwimage:Pathway:WP2904|250px||Mir302-367 Promoting Cardiomyocyte Proliferation}} | ||
|- | |- | ||
|width=100px|{{#pwImage:Pathway:WP1544|250px||MicroRNAs in cardiomyocyte hypertrophy}} | |width=100px|{{#pwImage:Pathway:WP1544|250px||MicroRNAs in cardiomyocyte hypertrophy}} | ||
Line 86: | Line 105: | ||
|width=100px|{{#pwimage:Pathway:WP1545|250px||miRNAs involved in DNA damage response}} | |width=100px|{{#pwimage:Pathway:WP1545|250px||miRNAs involved in DNA damage response}} | ||
|width=100px|{{#pwImage:Pathway:WP2249|250px||Metastatic Brain Tumor}} | |width=100px|{{#pwImage:Pathway:WP2249|250px||Metastatic Brain Tumor}} | ||
- | |width=100px|{{#pwimage:Pathway: | + | |width=100px|{{#pwimage:Pathway:WP673|250px||ErbB Signaling Pathway}} |
|- | |- | ||
|width=100px|{{#pwImage:Pathway:WP2431|250px||Spinal Cord Injury}} | |width=100px|{{#pwImage:Pathway:WP2431|250px||Spinal Cord Injury}} | ||
Line 96: | Line 115: | ||
|width=100px|{{#pwImage:Pathway:WP3971|250px||Role of Osx and miRNAs in tooth development}} | |width=100px|{{#pwImage:Pathway:WP3971|250px||Role of Osx and miRNAs in tooth development}} | ||
|width=100px|{{#pwImage:Pathway:WP3991|250px||miR-127 in mesendoderm differentiation}} | |width=100px|{{#pwImage:Pathway:WP3991|250px||miR-127 in mesendoderm differentiation}} | ||
- | |||
- | |||
- | |||
- | |||
|width=100px|{{#pwimage:Pathway:WP2910|250px||Mecp2 and Associated Rett Syndrome}} | |width=100px|{{#pwimage:Pathway:WP2910|250px||Mecp2 and Associated Rett Syndrome}} | ||
+ | |- | ||
+ | |width=100px|{{#pwimage:Pathway:WP2012|250px||miRs in Muscle Cell Differentiation}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP2029|250px||Cell Differentiation}} | ||
+ | |width=100px|{{#pwimage:Pathway:WP2261|250px||Signaling Pathways in Glioblastoma}} | ||
|width=100px|{{#pwImage:Pathway:WP2011|250px||REBF and miR33 in cholesterol and lipid homeostasis}} | |width=100px|{{#pwImage:Pathway:WP2011|250px||REBF and miR33 in cholesterol and lipid homeostasis}} | ||
- | |||
- | |||
|- | |- | ||
|width=100px|{{#pwImage:Pathway:WP2004|250px||miR-targeted genes in lymphocytes - TarBase}} | |width=100px|{{#pwImage:Pathway:WP2004|250px||miR-targeted genes in lymphocytes - TarBase}} | ||
Line 116: | Line 133: | ||
|width=100px|{{#pwImage:Pathway:WP2002|250px||miR-targeted genes in epithelium - TarBase}} | |width=100px|{{#pwImage:Pathway:WP2002|250px||miR-targeted genes in epithelium - TarBase}} | ||
[http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=tarbase/index TarBase] | [http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=tarbase/index TarBase] | ||
- | |width=100px|{{# | + | |width=100px|{{#pwImage:Pathway:WP1992|250px||TarBasePathway}} |
- | + | [http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=tarbase/index TarBase] | |
- | |width=100px|{{# | + | |width=100px|{{#pwImage:Pathway:WP2001|250px||miR-targeted genes in adipocytes - TarBase}} |
- | + | [http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=tarbase/index TarBase] | |
- | + | ||
|width=100px|{{#pwimage:Pathway:WP2858|250px||Ectoderm Differentiation}} | |width=100px|{{#pwimage:Pathway:WP2858|250px||Ectoderm Differentiation}} | ||
+ | |- | ||
+ | |width=100px|{{#pwImage:Pathway:WP2853|250px||Endoderm Differentiation}} | ||
|width=100px|{{#pwimage:Pathway:WP2857|250px||Mesodermal Commitment Pathway}} | |width=100px|{{#pwimage:Pathway:WP2857|250px||Mesodermal Commitment Pathway}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP1991|250px||SRF and miRs in Smooth Muscle Differentiation and Proliferation}} | ||
|} | |} |
Current revision
Image does not exist |
Image does not exist |
Image does not exist Ozpolat et al. Liposomal siRNA nanocarriers for cancer therapy Thomas et al. Eri1: a conserved enzyme at the crossroads of multiple RNA-processing pathways |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist Danielson and Das, Extracellular Vesicles in Heart Disease: Excitement for the Future? |
Image does not exist Gonzalez-Villasana et al. Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer |
Image does not exist Miyake et al. XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A |
Image does not exist |
Image does not exist Parasramka et al. Long non-coding RNAs as novel targets for therapy in hepatocellular carcinoma |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist Teng et al. H19 MVP-mediated exosomal sorting of miR-193a promotes colon cancer progression |
Image does not exist |
Image does not exist |
Image does not exist Shen et al. To Wnt or Lose: The Missing Non-Coding Linc in Colorectal Cancer |
Image does not exist |
Image does not exist Bei et al. Extracellular Vesicles in Cardiovascular Theranostics. |
Image does not exist |
Image does not exist Giza et al. Cellular and viral microRNAs in sepsis: mechanisms of action and clinical applications |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist Gharpure et al, FABP4 as a key determinant of metastatic potential of ovarian cancer |
Image does not exist Koupenova et al, Circulating Platelets as Mediators of Immunity, Inflammation, and Thrombosis |
Image does not exist Hulsmans et al, Cardiac macrophages promote diastolic dysfunction |
Image does not exist |
Image does not exist |
Image does not exist Cortez et al, Role of miRNAs in immune responses and immunotherapy in cancer |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |